Pfizer hires Catalent to make smaller format Advil using Optigel tech

By Gareth Macdonald

- Last updated on GMT


Related tags Pharmacology

Pfizer Inc. has awarded Catalent Pharma Solutions the long-term manufacturing contract for a smaller version of its over-the-counter (OTC) painkiller Advil (ibuprofen). 

The deal – financial terms of which were not disclosed – will see Catalent make Advil Liqui-Gels Minis at its facility in St. Petersburg, Florida, facility under an unspecified “long-term” supply agreement.

Pfizer launched the  Advil Liqui-Gels Mini capsules earlier this month, over the Independence Day weekend. 

They are smaller than previous versions of the drug thanks to Catalent’s Optigel Mini technology, which allows higher concentrations of active pharmaceutical ingredient (API) to be encapsulated in a single unit.

A spokeswoman told us the technology can be used to reduce the size of a standard capsule by up to 50%.

The contract manufacturing organisation (CMO) says drugs made using the Optigel Mini platform more patient-friendly and convenient, highlighting them as suitable for children and the elderly.

Catalent has made the original format AdvilLiqui-Gels capsules for Pfizer for 20 years.

The spokeswoman explained that: "Liqui-Gels Minis are produced using the same rotary-die process​" adding that "Catalent’s expertise in formulation allows for higher API concentrations in these smaller capsules."

Related topics Drug Delivery Delivery formulations

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Follow us


View more